1.AOYAGI T, TERRACINA K P, RAZA A, et al. Cancer cachexia, mechanism and treatment［J］. World J Gastrointest Oncol, 2015, 7(4):17-29.
2.KRZNARIC , JURETIC A, DOMISLOVIC V, et al. Ten years of Croatian national guidelines for use of eicosapentaenoic acid and megestrol acetate in cancer cachexia syndrome - Evaluation of awareness and implementation among Croatian oncologists［J］. Clin Nutr ESPEN, 2019, 33:202-206.
3.SHARMA R A, STEWARD W P, DAINES C A, et al. Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignancies［J］. Eur J Cancer, 2006, 42(14):2318-2325.
4.RIECHELMANN R P, BURMAN D, TANNOCK I F, et al. Phase II trial of mirtazapine for cancer-related cachexia and anorexia［J］.Am J Hosp Palliat Care, 2010, 27(2): 106-110.
5.DEWEY A, BAUGHAN C, DEAN T, et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia［J］. Cochrane Database Syst Rev, 2007, 2007(1):CD004597.
6.MAZZOTTA P, JENEY C M. Anorexia-cachexia syndrome: A systematic review of the role of dietary polyunsaturated fatty acids in the management of symptoms, survival, and quality of life［J］. J Pain Symptom Manage, 2009, 37(6):1069-1077.
7.RIES A, TROTTENBERG P, ELSNER F. A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: An EPCRC cachexia guidelines project［J］. Palliat Med, 2012, 26(4): 294-304.
8.PAPPALARDO G, ALMEIDA A1, RAVASCO P. Eicosapentaenoic acid in cancer improves body composition and modulates metabolism［J］. Nutrition, 2015, 31(4):549-55.
9.李世伟, 马怀幸, 李苏宜. ω-3多不饱和脂肪酸治疗癌性恶病质系统评价及荟萃分析［J］. 肠外与肠内营养, 2017, 24(1):28-32.
10.SATOU M, NAKAMURA Y, ANDO H, et al. Understanding the functional significance of ghrelin processing and degradation［J］. Peptides, 2011, 32(11):2183-2190.
11.FUJITSUKA N, UEZONO Y.Rikkunshito, a ghrelin potentiator, ameliorates anorexia- cachexia syndrome［J］. Front Pharmacol, 2014, 10(5):271.
12.GARCIA J M, FRIEND J, ALLEN S. Therapeutic potential of anamorelin, a novel, orally available ghrelin mimetic, in patients with cancer-related cachexia: A multicenter, randomized, double-blind, crossover, pilot study［J］. Supportive Care in Cancer, 2013, 21 (1): 129-137.
13.TEMEL J S, ABERNETHY A P, CURROW D C, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials［J］. Lancet Oncol, 2016, 17(4):519-531.
14.CURROW D, TEMEL J S, ABERNETHY A, et al. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia［J］.Ann Oncol, 2017, 28(8):1949-1956.
15.KATAKAMI N, UCHINO J, YOKOYAMA T, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)［J］. Cancer, 2018, 124(3):606-616.
16.HAMAUCHI S, FURUSE J, TAKANO T, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia［J］. Cancer, 2019, 125(23):4294-4302.
17.FUJITSUKA N, ASAKAWA A, UEZONO Y, et al. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival［J］. Transl Psychiatry, 2011, 1(7):e23-e33.
18.OHNISHI S, WATARI H, KANNO M, et al. Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02)［J］. J Gynecol Oncol, 2017, 28(5):e44.
19.SUN L L, LAI H Z, CHEN Z Z, et al. Modified Liujunzi decoction alleviates chemotherapy-induced anorexia in advanced non-small cell lung cancer: a propensity score matched case-control study［J］. Chin J Integr Med, 2020, 26(4):256-262.
20.CHEN J M, YANG T T, CHENG T S, et al. Modified Sijunzi decoction can alleviate cisplatin-induced toxicity and prolong the survival time of cachectic mice by recovering muscle atrophy［J］. J Ethnopharmacol, 2019, 233:47-55.
21.CHEN Y, CHEN H, SUN B. Chinese herbal medicine Sijunzi decoction alleviates liver cancer cachexia through downregulating TGF-β and IGF 1 signaling pathways［J］. Ann Oncol, 2019, 30(Supl.4):264.
22.ZHANG Y N, HAN X C, BING O Y, et al. Chinese herbal medicine baoyuan jiedu decoction inhibited muscle atrophy of cancer cachexia through antrogin-Ⅰ and MuRF-1［J］. Evid Based Complement Alternat Med, 2017, 2017:6268378.
23.ASP M L, TIAN M, WENDEL A A, et al. Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice［J］. Int J Cancer, 2009, 126(3):756-763.
24.PENNA F, BONETTOA, MUSCARITOLI M, et al. Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved［J］? Int J Cancer, 2010, 127(7):1706-1717.
25.HONG Y, LEE J H, JEONG K W, et al. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy［J］. J Cachexia Sarcopenia Muscle, 2019, 10(4):903-918.
26.HONORS M A, KINZIG K P. Chronic exendin-4 treatment prevents the development of cancer cachexia symptoms in male rats bearing the Yoshida sarcoma［J］. Horm Cancer, 2014, 5(1):33-41.
27.SOLOMON Z J, MIRABAL J R, MAZUR D J, et al. Selective androgen receptor modulators: current knowledge and clinical applications［J］. Sex Med Rev, 2019, 7(1):84-94.
28.CRAWFORD J, PRADO C M, JOHNSTON M A, et al. Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (power trials)［J］. Curr Oncol Rep, 2016, 18(6):37.
29.SALAZAR-DEGRACIA A, BUSQUETS S, ARGILS J M, et al. Effects of the beta2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia［J］. Biochimie, 2018, 149:79-91.
30.TOLEDO M, BUSQUETS S, PENNA F, et al. Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist［J］. Int J Cancer, 2016, 138(8):2021-2029.
31.MOLFINO A, AMABILE M I, ROSSI FANELLI F, et al. Novel therapeutic options for cachexia and sarcopenia［J］. Expert Opin Biol Ther, 2016, 16(10):1239-1244.
32.HATAKEYAMA S, SUMMERMATTER S, JOURDAIN M, et al. ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments［J］. Skelet Muscle, 2016, 6:26.
33.BAYLISS T J, SMITH J T, SCHUSTER M, et al. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer［J］. Expert Opin Biol Ther, 2011, 11(12):1663-1668.
34.PRADO B L, QIAN Y. Anti-cytokines in the treatment of cancer cachexia［J］. Ann Palliat Med, 2019, 8(1):67-79.
35.BERTI A, BOCCALATTE F, SABBADINI M G, et al. Assessment of tocilizumab in the treatment of cancer cachexia［J］. J Clin Oncol, 2013, 31(23):2970.
36.ANDO K, TAKAHASHI F, KATO M, et al. Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer［J］. PLoS One, 2014, 9(7):e102436.
37.MIYAMOTO Y, HANNA D L, ZHANG W, et al. Molecular pathways: Cachexia signaling-a targeted approach to cancer treatment［J］. Clin Cancer Res, 2016, 22(16):3999-4004.
38.OSULLIVAN COYNE G, BUROTTO M. MABp1 for the treatment of colorectal cancer［J］. Expert Opin Biol Ther, 2017, 17(9):1155-1161.
39.HONG DS, HUI D, BRUERA E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: An open-label, phase 1 dose-escalation and expansion study［J］. Lancet Oncol, 2014, 15(6):656-666.
40.FISHER GA. A phase Ⅲ study of xilonix in refractory colorectal cancer patients with weight loss［J］. J Clin Oncol, 2015, 33(suppl 3):685.
41.MCDONALD J J, MCMILLAN D C, LAIRD B J A. Targeting IL-1α in cancer cachexia: a narrative review［J］. Curr Opin Support Palliat Care, 2018, 12(4):453-459.
42.FINN R S, AHN D H, JAVLE M M, et al. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer［J］. Invest New Drugs, 2018, 36(6): 1037-1043.
43.QUAN-JUN Y, YAN H, YONG-LONG H, et al. Selumetinib attenuates skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation［J］. Mol Cancer Ther, 2017, 16(2):334-343.
44.Au E D, Desai A P, Koniaris L G, et al. The MEK-inhibitor Selumetinib attenuates tumor growth and reduces IL-6 expression but does not protect against muscle wasting in Lewis lung cancer cachexia［J］. Front Physiol, 2017, 7:682.
45.PRADO C M, BEKAII-SAAB T, DOYLE L A, et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma［J］. Br J Cancer, 2012, 106(10):1583-1586.
46.JATOI A, DAKHIL S R, NGUYEN P L, et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group［J］. Cancer, 2007, 110(6):1396-1403.
47.JATOI A, RITTER H L, DUECK A, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance nonsmall cell lung cancer patients (N01C9)［J］. Lung Cancer, 2010, 68(2):234-9. 67.
48.WIEDENMANN B, MALFERTHEINER P, FRIESS H, et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia［J］. J Support Oncol, 2008, 6(1):18-25.
